Misfitting implant-supported fixed dental prostheses (FDPs) may lead to an increased rate of biological and mechanical complications and further influence the long-term success of implants [1,2]. As the first step in fabricating a passively fitting implant-supported FDP, accurate implant impressions obtained using either conventional (CITs) or digital impression techniques (DITs) are crucial [2][3][4].CITs are a reliable and standard approach for transferring the positions of dental implants [5]. However, certain limitations exist, including high complexity, time consumption, material costs, storage issues, and unpleasant patient experiences [6,7]. Over the past several decades, DITs using intraoral scanners have been considered an advantageous alternative to CITs because they improve comfort and are more efficient [8,9]. However, the accuracy of DITs remains inconclusive, and a wide range of values (5.38-810 µm) is documented [10].Most recent studies regarding the accuracy of implant impression techniques are limited to laboratory study designs [11][12][13][14][15][16][17], and only a few clinical studies have been reported [18]. As defined by ISO 5725-1, accuracy comprises trueness and precision. Trueness describes the deviation of the obtained results from true reference values. However, a standard method for intraoral acquisition of the actual reference positions of implants has not yet been developed [3]. Precision describes the closeness of agreement between the results of repeated measurements on the same object. Although the precision of impression techniques can be evaluated in clinical studies by measuring the difference between repeated intraoral impressions [19][20][21], previous precision studies regarding implant impression techniques mainly employed in vitro designs [22][23][24][25][26], and clinical data remain very limited [27]. Compared with extraoral conditions, intraoral conditions involve more complex factors associated with the impression removal pathway, including temperature, humidity, saliva, tongue movements, limited spaces, and different ambient light conditions, which may influence the accuracy of the J Prosthodont Res. 2023; **(**):
Aim: Ovarian serous surface papillary borderline tumor (OSSPBT) is very rare. Combined with clinical and pathological features, we aim to investigate the multimodal ultrasound features of OSSPBT. Patients and Methods: There were only 18 patients diagnosed with OSSPBT among the 142 patients who were diagnosed with borderline serous ovarian tumor by pathology from June 2008 to December 2020 in our hospital. Their clinical data, conventional ultrasound, two-dimensional contrast-enhanced ultrasound (2D-CEUS), three-dimensional contrast-enhanced ultrasound (3D-CEUS) characteristics, pathology, and prognosis were retrospectively analyzed. Results: The 18 patients had no specific clinical symptoms. Multiple implantable nodules were found in 8 patients (44.4%), ascites in 13 patients (72.2%), and elevated carbohydrate antigen 125 (CA125) in 15 patients (83.3%). After excluding 2 misdiagnosed patients from 18 patients, 26 tumors in 16 patients (6 unilateral and 10 bilateral) were studied. Conventional ultrasound findings of OSSPBT showed that large solid masses around normal ovary without capsule, and numerous small dense anechoic areas were observed in the parenchyma of the lesion, with strong speckle echo (“blizzard” sign) of varying degrees. The 2D-CEUS and 3D-CEUS showed a normal ovary in the center surrounded by a radial blood supply of OSSPBT with thick and irregular branches. Histopathologically, the papillary fibrous stalk of OSSPBT had a large number of sand bodies and tortuous dilated microvessels. All patients had no recurrence after surgery, and two of them delivered successfully through assisted reproductive technology. Conclusion: OSSPBT has a good prognosis. Its conventional ultrasound is characterized by irregular solid masses surrounding normal ovaries and a large number of “blizzard” signs. It showed low enhancement of eccentricity with irregular radial branches centered on the ovary by CEUS.
Background This study aims to investigate whether indocyanine green (ICG) tumor imaging helps determine the safe surgical margin in laparoscopic hepatectomy. Patients and Methods Eighty-six patients with hepatic malignancies [including hepatocellular carcinoma (HCC) and colorectal liver metastasis (CRLM)] were included in this study. ICG-R15 testing was performed 5–7 days before surgery. Fluorescence staining of the tumor was detected by a fluorescent laparoscope, and the width of fluorescence band surrounding tumor was measured by an electronic vernier caliper. Results The positive rate of hepatic malignant lesions successfully stained by ICG fluorescence was 96.0% (95/99). HCC with better differentiation demonstrated non-rim fluorescence patterns, while cases with poor differentiation demonstrated rim patterns. CRLM uniformly demonstrated rim pattern. The width of fluorescence surrounding tumors was 0 in HCC with non-rim patterns. The minimum width of fluorescence surrounding tumors in poor differentiated HCC and CRLM were 2.4 ± 1.9 mm and 2.8 ± 2.5 mm, respectively, with no significant difference (P > 0.05). ICG fluorescence imaging revealed eight small lesions, which were not detected preoperatively in seven patients, of which five lesions were confirmed as malignancies by pathology. Conclusions Resection along the ICG fluorescence edge can supply a safe surgical margin only for CRLM, but not for HCC. Otherwise, ICG fluorescence tumor imaging can preliminarily determine the pathological type of hepatic malignancies and histological differentiation of HCC and help detect small lesions that cannot be detected preoperatively.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.